

DOCTOR'S ORDER SHEET -PHARMACY – ACTEMRA (tocilizumab) Place patient identification sticker here

Allergies:	NKA Height Weight _	kg
QD, QC	****UNAPPROVED ABBREVIATIONS**** D, MgSO₄, MSO₄, MS, IU, U or -u, ug, Use of a Trailing Zero (X.0mg), Lack of a Leading Zero(
DATE TIM	E ORDERS	NURSE SIGNATURE
	Assign to Outpatient status	
	PREMEDICATIONS:	
	0.9% sodium chloride (NS) IV at KVO	1
	No pre-medications necessary	
	methylprednisolone sodium succinate injectionmg IV x 1 dose 30 mins prior to infusion	
	diphenhydraminemg IV x1 dose 30 mins prior to infusion	
	diphenhydraminemg PO x 1 dose 30 mins prior to infusion	
	acetaminophen 650mg PO x 1 dose 30 mins prior to infusion	
	MEDICATION:	
	Actemra (tocilizumab) in 0.9% NS 100ml IV infusion	
	Dose: 4mg/kg = Total Dosemg	
	Bmg/kg = Total Dosemg	
	Route: Intravenous	
	Frequency: Once every 4 weeks	
	Infusion Duration: 60 minutes	
	If infusion-related reaction:	<u>_</u>
	1.) STOP infusion immediately;	
	 2.) Increase 0.9% sodium chloride (NS) infusion to wide open rate; 3.) Administer PRN medications per infusion reaction medication ordered; 	
	4.) Call Max Cart;	
	5.) Notify MD	
	INFUSION REACTION MEDICATIONS:	
	albuterol inhalation nebulizer solution 2.5mg/0.5ml (concentrated solution)	_
	(Note: dilute with 2.5ml of NS for an albuterol 2.5mg/3ml dose)	
	Dose: 2.5mg via nebulizer as needed for shortness of breath/wheezing	-
	diphenhydrAMINE injectable	
	Dose: 25mg IV x 1 dose for uticaria, pruitis, shortness of breath. May repeat in 15 minutes if	-
	symptoms not resolved	
	EPINEPHrine 1mg/ml (1:1000) injectable	
	Dose: 0.3mg IM x1 dose as needed for anaphylaxis	
	methylPREDNISolone sodium succinate 125mg injection	
	Dose: 125mg IV x1 dose as needed for hypersensitivity	
	NURSING ORDERS:	
	 Weight should be recorded at every visit. Notify physician if weight changed 10% or greater from baseline]
	Ensure patient has had TB test or QuantiFERON-TB assay for latent TB prior to start of treatment	
	 Continue with infusion only if patient meets the following criteria: ANC ≥ 2,000 (first dose) or ≥ 1,000 (subsequent doses 	
	 Platelets ≥ 100,000 AST/ALT < 1.5 x ULN 	
	• Verify lipid panel drawn prior to initial therapy, at 4 to 8 weeks after initial treatment and every 6 months during treatment. If lipid panel not drawn prior to treatment, instruct patient to have labs	
	 drawn and notify provider, but proceed with infusion. Do not administer tocilizumab and notify provider if patient has a temperature >100°F, complains 	
	 of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection Monitor patient for signs/symptoms of hypersensitivity during infusion and for 30 mins post- 	
	infusion Discontinue IV line when therapy complete and patient stabilized	

USE BALL POINT PEN FAX TO PHARMACY **REFERENCES:** Actemra Prescribing Information

Qualified Medical Provider signature

Date

Time

